

# Gene Editing Therapeutics Market

<https://marketpublishers.com/r/GEF8D247F76CEN.html>

Date: August 2024

Pages: 111

Price: US\$ 5,500.00 (Single User License)

ID: GEF8D247F76CEN

## Abstracts

### Report Scope:

This report highlights the current and future market potential of gene editing therapeutics and provides a detailed analysis of the drivers, restraints and opportunities in this market. It also surveys the competitive environment, including coverage of the pipeline activities adopted by market players, and it includes market projections for 2029. Also included are company profiles of key players, featuring detailed information regarding each company's business segments, financials, product portfolios and recent developments.

### Report Includes:

15 data tables and 42 additional tables

An analysis of the current and future global markets for gene editing therapeutics

Analyses of global market trends, with market revenue data (sales figures) for 2021-2023, estimates for 2024, and projected CAGRs through 2029

Estimates of the market size and revenue forecasts for the global gene editing therapeutics market, with market share analysis by region

Discussion of the market dynamics, opportunities, and challenges, as well as emerging technologies

Overview of sustainability trends and ESG developments in the industry, with emphasis on the ESG practices of leading companies, their ESG rankings, and

consumer attitudes

Competitive intelligence, including companies' market shares, recent M&A activity, and venture funding

Company profiles of major players within the industry, including CRISPR Therapeutics, Vertex Pharmaceuticals, and Intellia Therapeutics

## Contents

### **CHAPTER 1 EXECUTIVE SUMMARY**

Market Outlook  
Scope of Report  
Market Summary

### **CHAPTER 2 MARKET OVERVIEW**

Introduction  
Genome-Editing Tool Types  
Meganucleases  
Zinc Finger Nucleases  
Transcription Activator-like Effector Nucleases  
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein  
Gene editing Therapeutics

### **CHAPTER 3 MARKET DYNAMICS**

Market Dynamics Snapshot  
Market Drivers  
Increasing Prevalence of Chronic Disease  
Increasing Prevalence of Rare Genetic Disorders  
Precision Medicine  
Increasing Strategic Initiatives  
Market Restraints  
Stringent Regulatory Frameworks and Time-Consuming Approval Processes  
High Cost of Treatment  
Adverse Events and Long-Term Monitoring  
Lack of Skilled Workforce  
Off-Target Impact  
Market Challenges  
Patent Disputes  
Governmental Policies and Regulations  
Ethical Issues  
Market Opportunities

## **CHAPTER 4 EMERGING TECHNOLOGIES AND DEVELOPMENTS**

Introduction  
Base Editing  
Prime Editing  
Cas-Clover and Cas-FOKI  
CRISPR Interference and CRISPR Activation  
RNA Editing  
Artificial Intelligence in Genome Editing

## **CHAPTER 5 PIPELINE ANALYSIS**

Overview  
Clinical Trial Analysis Based on Technology  
Clinical Trial Analysis Based on Diseases  
Designations for Pipeline Drugs

## **CHAPTER 6 PATENT ANALYSIS**

## **CHAPTER 7 MARKET ANALYSIS**

Introduction  
Casgevy  
Market Overview  
Market Analysis  
Market by Region  
North America  
Europe  
Emerging Markets

## **CHAPTER 8 COMPETITIVE INTELLIGENCE**

Strategic Initiatives  
Competitive Landscape

## **CHAPTER 9 SUSTAINABILITY IN THE GENE EDITING THERAPEUTICS MARKET: ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) PERSPECTIVES**

Introduction

ESG Practices in the Gene Editing Companies  
Concluding Remarks from BCC Research

**CHAPTER 10 APPENDIX**

Methodology

Sources

Acronyms

Company Profiles

ALLOGENE THERAPEUTICS

BEAM THERAPEUTICS

CARIBOU BIOSCIENCES INC.

CRISPR THERAPEUTICS

EDITAS MEDICINE

INTELLIA THERAPEUTICS INC.

PRECISION BIOSCIENCES

SANGAMO THERAPEUTICS

VERTEX PHARMACEUTICALS INC.

VERVE THERAPEUTICS INC.

VOR BIO

## List Of Tables

### LIST OF TABLES

- Summary Table : Global Market for Gene Editing Therapeutics, Through 2029
- Table 1 : Comparison of Genome-Editing Tools
- Table 2 : U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
- Table 3 : Global Cases and Deaths Due to Various Cancers, 2022
- Table 4 : Gene Editing Index Ratings, 2020
- Table 5 : Rating Guide
- Table 6 : Comparison of Cas9-derived Proteins with Regular SpCas9
- Table 7 : Gene Editing Therapeutic Trials in Phase I, Till May 2024
- Table 8 : Gene Editing Therapeutic Trials in Phase I/II, II and III, Till May 2024
- Table 9 : Casgevy Label Expansion Studies, Till May 2024
- Table 10 : Examples of Some Pipeline Drugs and Their Designations, as of May 2024
- Table 11 : Patents on CRISPR Therapeutics, Published in 2021
- Table 12 : Patents on CRISPR Therapeutics, Published in 2022
- Table 13 : Patents on CRISPR Therapeutics, Published in 2023
- Table 14 : Global Market for Gene Editing Therapeutics, Through 2029
- Table 15 : Global Market for Gene Editing Therapeutics, by Region, Through 2029
- Table 16 : Strategic Initiatives in the Gene Editing Therapeutics Market, 2020–2024
- Table 17 : Venture Funding for Startups, 2023
- Table 18 : ESG Initiatives/Practices by Various Gene Editing Companies, 2023
- Table 19 : ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
- Table 20 : Report Information Sources
- Table 21 : Glossary of Terms Used in This Report
- Table 22 : Allogene Therapeutics: Company Snapshot
- Table 23 : Allogene Therapeutics: Financial Performance, FY 2022 and 2023
- Table 24 : Allogene Therapeutics: News/Key Developments, 2020-2024
- Table 25 : Beam Therapeutics: Company Snapshot
- Table 26 : Beam Therapeutics: Financial Performance, FY 2022 and 2023
- Table 27 : Beam Therapeutics: News/Key Developments, 2021-2023
- Table 28 : Caribou Biosciences Inc.: Company Snapshot
- Table 29 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
- Table 30 : Caribou Biosciences Inc.: News/Key Developments, 2021-2024
- Table 31 : CRISPR Therapeutics: Company Snapshot
- Table 32 : CRISPR Therapeutics: Financial Performance, FY 2022 and 2023

Table 33 : CRISPR Therapeutics: Product Portfolio

Table 34 : CRISPR Therapeutics: News/Key Developments, 2021-2024

Table 35 : Editas Medicine: Company Snapshot

Table 36 : Editas Medicine: Financial Performance, FY 2022 and 2023

Table 37 : Editas Medicine: News/Key Developments, 2022-2024

Table 38 : Intellia Therapeutics Inc.: Company Snapshot

Table 39 : Intellia Therapeutics Inc.: Financial Performance, FY 2022 and 2023

Table 40 : Intellia Therapeutics Inc.: News/Key Developments, 2021-2024

Table 41 : Precision Biosciences: Company Snapshot

Table 42 : Precision Biosciences: Financial Performance, FY 2022 and 2023

Table 43 : Precision Biosciences: News/Key Developments, 2020-2024

Table 44 : Sangamo Therapeutics: Company Snapshot

Table 45 : Sangamo Therapeutics: Financial Performance, FY 2022 and 2023

Table 46 : Sangamo Therapeutics: News/Key Developments, 2024

Table 47 : Vertex Pharmaceuticals Inc.: Company Snapshot

Table 48 : Vertex Pharmaceuticals Inc.: Financial Performance, FY 2022 and 2023

Table 49 : Vertex Pharmaceuticals Inc.: Product Portfolio

Table 50 : Vertex Pharmaceuticals Inc.: News/Key Developments, 2023 and 2024

Table 51 : Verve Therapeutics Inc.: Company Snapshot

Table 52 : Verve Therapeutics Inc.: Financial Performance, FY 2022 and 2023

Table 53 : Verve Therapeutics Inc.: News/Key Developments, 2019-2024

Table 54 : Vor Bio: Company Snapshot

Table 55 : Vor Bio: Financial Performance, FY 2022 and 2023

Table 56 : Vor Bio: News/Key Developments, 2020-2024

## List Of Figures

### LIST OF FIGURES

Summary Figure : Global Market for Gene Editing Therapeutics, 2021-2029

Figure 1 : Genome-Editing Outcomes

Figure 2 : Endonucleases Used in Gene Editing Technologies

Figure 3 : Advances in Therapeutic Strategies to Treat Life-Threatening Diseases

Figure 4 : CRISPR/Cas9 Therapeutics Timeline, Since 1987–Present

Figure 5 : CRISPR/Cas9 Therapeutics Delivery Platform

Figure 6 : Delivery Method

Figure 7 : Market Dynamics of Gene Editing Therapeutics Market

Figure 8 : Genetic Disorders

Figure 9 : Emerging Technologies in the Genome-Editing Therapeutics Market

Figure 10 : Emerging Therapeutics Applications for RNA Editing by Cas Enzymes

Figure 11 : Articles on Gene Editing Therapeutics in PubMed, 2004-2024

Figure 12 : Share of Clinical Trials on the Genome-Editing Market, by Technology, Through May 2024

Figure 13 : Genome-Editing Clinical Trials, by Diseases

Figure 14 : Genome-Editing Clinical Trials, by Trial Phase

Figure 15 : Genome-Editing Clinical Trials, by Trial Status

Figure 16 : Patents Documented, by Top Owners, 2021-2024

Figure 17 : Patents Documented, by Type, 2021-2024

Figure 18 : Patents Documented, by Type, 2021-2024

Figure 19 : Common Strategies Proposed for the Therapeutic Intervention for  $\beta$ -thalassemia and Sickle Cell Disease

Figure 20 : Caribou Biosciences Inc.: Revenue Share, by Country/Region, FY 2023

Figure 21 : Vertex Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2023

Figure 22 : Vertex Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2023



## I would like to order

Product name: Gene Editing Therapeutics Market

Product link: <https://marketpublishers.com/r/GEF8D247F76CEN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GEF8D247F76CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970